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Abstract
Gorlin syndrome (MIM 109,400), a cancer predisposition syndrome related to a constitutional pathogenic variation 
(PV) of a gene in the Sonic Hedgehog pathway (PTCH1 or SUFU), is associated with a broad spectrum of benign and 
malignant tumors. Basal cell carcinomas (BCC), odontogenic keratocysts and medulloblastomas are the main tumor types 
encountered, but meningiomas, ovarian or cardiac fibromas and sarcomas have also been described. The clinical features and 
tumor risks are different depending on the causative gene. Due to the rarity of this condition, there is little data on phenotype-
genotype correlations. This report summarizes genotype-based recommendations for screening patients with PTCH1 and 
SUFU-related Gorlin syndrome, discussed during a workshop of the Host Genome Working Group of the European branch 
of the International Society of Pediatric Oncology (SIOPE HGWG) held in January 2020. In order to allow early detec-
tion of BCC, dermatologic examination should start at age 10 in PTCH1, and at age 20 in SUFU PV carriers. Odontogenic 
keratocyst screening, based on odontologic examination, should begin at age 2 with annual orthopantogram beginning around 
age 8 for PTCH1 PV carriers only. For medulloblastomas, repeated brain MRI from birth to 5 years should be proposed for 
SUFU PV carriers only. Brain MRI for meningiomas and pelvic ultrasound for ovarian fibromas should be offered to both 
PTCH1 and SUFU PV carriers. Follow-up of patients treated with radiotherapy should be prolonged and thorough because 
of the risk of secondary malignancies. Prospective evaluation of evidence of the effectiveness of these surveillance recom-
mendations is required.
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Introduction
Gorlin syndrome (GS) (MIM 109,400), also called nevoid 
basal cell carcinoma syndrome (NBCCS) or basal cell nevus 
syndrome (BCNS), is an autosomal dominant inherited 
syndrome characterized by diverse developmental defects 
including macrocephaly, hypertelorism, skeletal anomalies, 
palmar and/or plantar pitting and a predisposition to various 
tumors. These can be malignant, such as basal cell carcino-
mas (BCC) and medulloblastoma, or benign such as kerato-
cystic odontogenic tumors and ovarian or cardiac fibromas.
Due to the rarity of the syndrome and the variability of 
clinical signs, diagnosis of GS may be difficult [1]. These 
factors led to the definition of clinical diagnostic criteria 
using a combination of major and minor criteria on which 
several groups have agreed (Table 1).
The genetic basis of the syndrome is the presence of a 
constitutional alteration in a gene within the Sonic Hedge-
hog pathway. Most GS cases are associated with heterozy-
gous PTCH1 pathogenic or likely pathogenic variants (PV). 
More recently, germline variants in SUFU [2] and rarely 
PTCH2 [3] genes have also been described in patients with 
a Gorlin phenotype. Due to the rarity of this condition, there 
is little data on phenotype-genotype correlations [4].
Recently, the Host Genome Working Group (HGWG) was 
established in the European branch of the International Soci-
ety of Pediatric Oncology (SIOPE) with the aim of improv-
ing care for patients with pediatric cancer predisposition 
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syndromes. One of the issues addressed during the first 
workshop of this group, held in January 2020, was the devel-
opment of surveillance guidelines in several predisposition 
syndromes. Several experts in the field of pediatric oncoge-
netics, including clinical geneticists and pediatric oncolo-
gists from European countries, participated in the meeting. 
Based on the current data, the experts’ recommendations and 
the consensus reached, the SIOPE HGWG now proposes a 
genotype-based surveillance program for patients with GS, 
but this is not yet fully evidence based. This report sum-
maries the discussions and expert recommendations of this 
working group.
Genetic associations
Population incidence for PTCH1 and SUFU related 
Gorlin syndrome
GS is suspected on phenotypic criteria and clinical diag-
nosis is established in a patient with two major diagnostic 
criteria and one minor diagnostic criterion or one major and 
three minor diagnostic criteria. (Table 1) [1, 5]. This can be 
molecularly confirmed by genetic analysis of the PTCH1, 
PTCH2 and SUFU genes. All features of GS except odon-
togenic keratocysts [4, 6] can be present in SUFU-related 
GS, but GS clinical features are less prominent in people 
with germline SUFU PV and many will not meet GS cri-
teria even in later life [6]. Current testing in Manchester 
of patients meeting GS clinical criteria show that 134/193 
(69.4%) patients have an identifiable germline PTCH1 PV, 
11/193 (5.7%) have an identifiable SUFU PV and 48 (24.9%) 
have no identifiable PV in SUFU, PTCH1 or PTCH2. No PV 
of PTCH2 has been identified in this series, thus this gene is 
probably rarely involved in GS pathogenesis and was there-
fore not taken into consideration in these recommendations. 
The estimated birth incidence of clinical GS is 1 in 14,963 
[7], suggesting that most of those with germline PTCH1 PVs 
(estimated frequency 1 in 3356-gnomAD; https:// gnomad. 
broad insti tute. org/) may never reach a clinical diagnosis. As 
the clinical signs of GS are even less prominent in patients 
with germline SUFU variant, a large number of SUFU PV 
carriers probably remain undiagnosed.
Tumor risk
Most patients with GS develop several benign and malig-
nant tumors, most often at a young age. There are some 
differences in the clinical features and incidence of tumor 
occurrence depending on the gene involved (Table 2). Even 
though it is dominated by BCC and keratocystic odontogenic 
tumors, the spectrum of tumors associated with GS is large. 
Ovarian fibromas, meningiomas and medulloblastomas 
appear to be more frequent in patients with constitutional 
pathogenic SUFU variants than PTCH1 variants [4].
Analysis of the risk of each tumor type according to 
the genotype is still preliminary due to the rarity of this 
syndrome and bias of ascertainment, since most patients 
belonging to Gorlin cohorts have been identified after the 
occurrence of multiple odontogenic keratocysts or BCCs, 
whereas most SUFU variants described so far were identi-
fied in young children with medulloblastoma.
Basal cell carcinoma (BCC)
GS is characterized by multiple BCCs with a median age-
at-onset of the first BCC of 33y (95% CI 28–37) [8]. In a 
large series from Manchester of 202 patients with Gorlin 
syndrome, the cumulative incidence of BCC was 13% in 
males and 12% in females by age 20, 76,5% in females 
and 80% in males by age 50 [8]. The risk of BCC seems 
to be lower in African Americans and in Japanese than in 
Table 1  Clinical diagnostic criteria for Gorlin syndrome
Diagnosis of Gorlin syndrome requires
Two major diagnostic criteria and one minor diagnostic criterion or one major and three minor diagnostic criteria
Identification of a heterozygous germline PTCH1 or SUFU pathogenic variant on molecular genetic testing
Major criteria Minor criteria
(1) BCC prior to 20 years of age or excessive numbers of BCCs (> 5 
BCC) out of proportion to prior sun exposure and skin type
(2) Odontogenic keratocyst of the jaw prior to 20 years of age
(3) Palmar or plantar pitting
(4) Lamellar calcification of the falx cerebri;
(5) Medulloblastoma, typically desmoplastic
(6) First degree relative with BCNS
(1) Rib anomalies; bifid/splayed/extra ribs
(2) Other specific skeletal malformations and radiologic changes 
(i.e., vertebral anomalies, kyphoscoliosis, short fourth metacarpals, 
postaxial polydactyly)
(3) Macrocephaly; (OFC > 97th centile) (4) Cleft lip/palate
(5) Ovarian/cardiac fibroma
(6) Lymphomesenteric or pleural? cysts
(7) Ocular abnormalities (i.e., strabism, hypertelorism, congenital 
cataracts, glaucoma, coloboma)
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Caucasian patients from America or Europe [9, 10]. The 
risk of BCC seems to be greatly increased by irradiation 
[9]. There is some evidence for modifier genes especially 
the ‘red hair’ MC1R variant polymorphism [11] which 
supports some familial clustering of features beyond the 
PTCH1 variant.
The risk of BCC in adult patients with germline SUFU 
mutations has not been estimated yet. Several SUFU PV 
carriers identified in GS cohorts have been diagnosed with 
multiple BCC [12–15], but most SUFU PVs were identi-
fied in infants treated for a medulloblastoma who were 
young at the time of clinical report and therefore their risk 
of BCC in adulthood cannot be assessed. In their relatives, 
the risk of BCC in adults is much lower than in classical 
GS related to PTCH1 PVs [6] suggesting that the risk of 
BCC in SUFU PV carriers is much lower than in PTCH1 
PV carriers. Indeed, in a series of 22 SUFU PV carriers 
ascertained through a medulloblastoma, only one among 
34 relatives (median age at last follow-up 51.3 years) car-
rying a SUFU PV had been diagnosed with a BCC [6].
Odontogenic keratocysts (Jaw cysts)
Odontogenic keratocysts, are benign neoplasms of odon-
togenic origin. They have been described in 75–89% of 
patients with GS and may be the first sign of GS. These 
tumors seem to be restricted to PTCH1 associated GS [4] 
whereas patients with SUFU PV are probably spared from 
this risk. In most series, first odontogenic keratocysts are 
diagnosed during the second decade of life, but jaw cysts 
have been diagnosed in young children during the first 
years of life. Even though these tumors grow slowly, their 
early detection is important in order to limit the impact 
of surgery on the growth and development of the maxil-
lofacial complex.
Medulloblastomas
Medulloblastoma with desmoplastic or extensive nodular-
ity histology is the main GS-associated pediatric malignant 
tumor. Most tumors described so far occurred before the 
age of 3 years. In addition, in the context of SUFU PVs, 
families with several children affected by medulloblastomas 
have been described [6, 16]. In a large series of medulloblas-
tomas screened for germline mutations, all SUFU or PTCH1 
PVs were observed exclusively in the SHH-medulloblastoma 
(SHH-MB) subgroup, with a frequency of 17/80 (21%) and 
18/170 (11%) in infant and pediatric SHH MB, respectively 
[17].
There are currently no direct estimates of the incidence 
of SUFU and PTCH1 PV carriers in the general population 
and no unbiased estimates of the risk of childhood medul-
loblastoma for each condition. The great majority of testing 
of SUFU is for childhood medulloblastoma and only limited 
testing has been carried out to identify healthy carriers in 
those families [17–19]. In the largest study thus far, Waszak 
et al. in 2018 [17], found a germline SUFU or PTCH1 PV 
in 20/1022 (2%) patients with medulloblastoma (9 PTCH1, 
11 SUFU). However, just over 200 of the Waszak series 
were over 18 years of age (Table 3), thus 11/800 (1.4%) 
of childhood medulloblastoma had a SUFU PV and 9/800 
Table 2  Tumor risk in GS 
patients: main series from the 
literature
BCC Basal cell carcinomas. The definition varied according to authors: all BCC for Kimosis and 
Endo, > 10 BCC for Evans, multiple or before age 20 for Shanley
















Median age at last follow-up 35 34.5 33.1 45 42 47
BCC* 90 (75%) 71 (80%) 56 (37.8%) 61 (48%) 4 (44%) 21 (45%)
KCOT 85/113 (75%) 78 (81%) 136 (86%) 79 (47%) 0 (0%) 16 (31%)
Medulloblastoma 1 (0.8%) 4 (4%) 4/120 (3%) 3 (2%) 3 (33%) 0
Meningioma 1 (0.8%) 2/42 (5%) 0 2 (22%) 2 (1.6%)
Ovarian fibroma 9/63 (14%) 9/52 (17%) 5/40 (12%) 4 (6%) 3 (43%) 4 (15%)
Cardiac fibroma 2/95 (2%) 2 (1%) 0 0
Table 3  Studies estimating the proportion of childhood medulloblas-
toma caused by SUFU or PTCH1 germline variants
Number of patients 
with MB tested
SUFU PTCH1
Brugières [2] 131 8 (6.1%)
Waszak child-
hood only [1]
800 11 (1.3%) 9 (1.1%)
Wang [3] 129 1 (0.7%) 1 (0.7%)
Total 1060 20 (1.8%) 10 (0.9%)
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(1.1%) had a PTCH1 PV. Brugieres et al. in 2012 found a 
much higher incidence of SUFU PVs, 8/131 (6.1%), [18] 
whereas Wang et al. found only one PV each for SUFU and 
PTCH1 in their series of 129 medulloblastomas (0.8%) [19]. 
These differences may be related to the distribution of age-
at-diagnosis and histological subtypes in the different series. 
Taking combined data from the three series 20/1060 (1.9%) 
had a SUFU PV and 10/929 (1.1%) had a PTCH1 PV.
A direct estimate of medulloblastoma risk in child-
hood can be derived from a population-based study in the 
Manchester region of NW England from 1954 to 1989. 
In 36 years of assessment, 173 childhood medulloblasto-
mas were registered in the Manchester Childhood tumors 
registry [20]. This gives an annual incidence of 4.8 in an 
average childhood population of 800,000 or 0.6/100,000 
in the Manchester region of NW England. The childhood 
risk of medulloblastoma would therefore be 16 (16 years 
of childhood risk) × 0.6 per 100,000 = 9.6 per 100,000 or 1 
in 10,400. Three patients of that series of 173 (1.73%) have 
subsequently been found to have a germline SUFU PV with 
two probable PTCH1 PVs (1.15%) [13, 21]. As such, the 
likelihood of a childhood SUFU related medulloblastoma 
is 9.6 × 0.0173 = 0.166 per 100,000 or 1 in 601,400. The 
population frequency of SUFU PVs can be estimated from 
gnomAD (https:// gnomad. broad insti tute. org/). Only three 
clearly pathogenic variants (excluding truncating variants 
in the last exon) were found in an average population sample 
of 124,185 people (1 in 41,395), although one was Afri-
can and the other Finnish. Therefore the population esti-
mate for European (non-Finnish) was 1 in 55,400. Taking 
these two estimates together, this would mean an estimated 
penetrance for medulloblastoma associated with a SUFU 
variant of 7–9.2%. Likewise, the estimate for medulloblas-
toma associated with PTCH1 from gnomAD was 1 in 3356, 
giving an estimated penetrance of 0.37%. These estimates 
are about 1/3rd of those from estimated risks in Gorlin syn-
drome families [13]. An alternative indirect estimate based 
on an aggregate of around 2% for SUFU PVs in childhood 
medulloblastoma and 1% for PTCH1 PVs from Table 3 is 
shown in Table 4. This generates almost identical estimates 
for each gene.
Considering the high incidence of PTCH1 and SUFU 
PVs in medulloblastomas, and in particular SHH-MBs in 
young children, experts recommend a germline PTCH1 and 
SUFU PVs screening for all children with SHH-MB, espe-
cially those diagnosed before the age of 5. The identification 
of a predisposition syndrome for medulloblastoma caused 
by a germline PV in SUFU or PTCH1 gene is fundamen-
tal, because the presence of an underlying genetic anomaly 
can have an impact on the therapeutic management, due to 
the different behavior of SUFU or PTCH1-related medullo-
blastomas, including differences in their responses to SHH 
inhibitors [22]. The best therapeutic strategy for this group 
of patients still has to be assessed. In addition, identifying 
SUFU PVs in these young patients may have a major impact 
on familial genetic counseling and surveillance of young 
relatives carrying the PV, especially siblings [16].
Meningiomas
Meningiomas have been reported in 0.8–5% of people in 
large series’ of GS [4, 9, 23, 24]. Meningiomas are probably 
more frequent in SUFU related GS than in PTCH1 related 
GS. Indeed, in the Manchester cohort, the incidence of men-
ingiomas was much higher in SUFU PV carriers (4/9) than 
in patients with a PTCH1 PV (2/126). Meningiomas have 
also been described, mostly as case reports, in patients with 
SUFU variants, either as the first brain tumor [12, 14, 25] 
or, more frequently, after irradiation for a medulloblastoma 
[6, 13, 26, 27]. Most de novo meningiomas described so far 
occurred after the age of 40, whereas they occurred earlier 
in patients previously treated for a medulloblastoma. In addi-
tion, two multigenerational families with meningiomas as 
the major feature in multiple affected family members have 
been associated with an inherited germline SUFU variant 
[12, 25].
Ovarian fibromas or fibrothecomas
Ovarian fibromas or fibrothecomas are benign sex-cord stro-
mal tumors which have been described in 6–43% of female 
patients with GS. They are usually revealed by abdominal 
discomfort due to compression of adjacent organs when they 
become large or by acute pain due to adnexal torsion. Their 
incidence is probably underestimated, since most tumors are 
asymptomatic. With systematic screening by pelvic ultra-
sound, they have been detected in 9/52 (17%) females with 
de GS in the NIH cohort [9] and 10% in the Manchester 
cohort [4]. The main characteristics of GS-associated ovar-
ian fibroma are their bilaterality and the presence of calci-
fication. Most sporadic tumors are diagnosed in adults, but 
ovarian fibroma has been described in prepubertal girls in 
Table 4  Alternative estimate of SUFU and PTCH1 based on indirect 
estimates from UK population incidence
a Based on gnomAD 1 in 41
Children in UK (0–16 years) 11,759,000
Annual brain tumour incidence in children 400
Incidence annual (1 in x) 29,397.5
Incidence during childhood (1 in x) 1837.3
Medulloblastoma in childhood 20% (1 in x) 9186.72
Medulloblastoma with germline SUFU PV (1 in x)a 45,9335.94
% SUFU PV with medulloblastoma 9.01%
Medulloblastoma with germline PTCH1 PV (1 in x) 91,8671.9
% PTCH PV with medulloblastoma 0.37%
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GS [28, 29]. Data from the Manchester cohort suggest that 
ovarian fibroma could be more frequent in SUFU PV female 
carriers (3/7) than in PTCH1 related GS (4/68) or in patients 
in whom no PV was identified (4/27). Early diagnosis is 
important to allow detection of small tumors, resectable by 
minimal-access surgery.
Cardiac fibroma
Cardiac fibroma is another hallmark tumor of GS. These 
tumors have been described in 1–3% of patients in large GS 
series [1, 10]. Most patients are diagnosed in utero or during 
the first years of life, but diagnoses later in life up to 60 years 
have been reported [30].
Other tumors
A wide spectrum of other tumors has been reported, such 
as sarcomas, including rhabdomyosarcomas [6, 31–33] and 
thyroid carcinomas [6, 10, 34]. Due to their extreme rarity, 
the relative risk of these tumors in patients with GS has not 
been established. In addition, multiple tumor types, includ-
ing sarcomas and Wilms tumors, have been described in 
patients with GS due to 9q22.3 microdeletion encompassing 
the PTCH1 locus [35, 36].
Recommendations for screening
Several publications including recommendation for cancer 
surveillance in GS have already been published [37, 38]. 
However, since data on tumor risks according to the gene 
involved were not published at that time, the European 
group thought it was useful to redefine surveillance guide-
lines adapted to the phenotype. The WHO criteria for cancer 
surveillance programs [39] have been taken into considera-
tion when discussing these recommendations, even though 
the rarity of this condition did not allow provision of any 
evidence of the effectiveness of the strategy proposed, espe-
cially for pediatric tumors.
Considering the difference of incidence of each tumor 
type in PTCH1 and SUFU PV carriers, the participants felt 
that screening should be adapted to the genetic background 
(PTCH1- or SUFU-associated GS) (Table 5). The HGWG 
group propose expert recommendations (not of proven evi-
dence) that are similar to those previously published for 
GS associated with PTCH1 PV, but the updated analysis 
of tumor risk associated with SUFU PV led to refined rec-
ommendations for screening for these patients. In all cases, 
patients should be followed annually by a medical geneticist 
or pediatric/adult oncologist familiar with the syndrome to 
check for non-tumoral manifestation of the syndromes, edu-
cate on alarming symptoms and to ensure that all screen-
ing procedures have been performed. In addition, patients/
parents and their primary physician should be informed 
of the tumor risks associated with the syndrome, so that 
adequate investigation can be performed urgently in case 
of symptoms.
Basal cell carcinomas
Even though the risk of BCC is probably lower in SUFU-
related GS than in PTCH1-related GS, a yearly skin exami-
nation by an experienced dermatologist should be offered 
in both groups of patients. The age of starting should be 
10 years for PTCH1-PV carriers and 20 years for patients 
with SUFU PVs. In both groups of patients, dermatological 
examination should begin earlier in people who have had 
previous radiotherapy in the first years after treatment com-
pletion. The interval between dermatological examinations 
Table 5  Screening recommendations for patients with GS
Tumors Methods for screening Indications for PTCH1 variants carriers Indications for SUFU variants carriers
BCC Dermatologic examination Annually beginning at 10 Earlier if previous 
radiotherapy
Annually beginning at 20
Earlier if previous radiotherapy
KCOT Dental examination Ortho-
panthogram (consider 
MRI)
Annually beginning at 2
Annually beginning at 8
Medulloblastomas Brain MRI (without con-
trast agent)
The first can be performed 
with a contrast agent
Neurological examination. Brain MRI, only if 
symptoms or neurological signs appear
Every 3–4 months during the first 3 years then 
every 6 months until 5 years
Meningioma Brain MRI Every 3–5 years beginning at age 30 for 
patients with no previous MB and after heal-
ing of the MB in other patients
Ovarian tumors Pelvic ultrasound Once at the end of adolescence (18 years) Every 3 years beginning at age 5 years
Cardiac fibroma Echocardiogram At the time of diagnosis of GS, ideally in the 
first 6 months of life
At the time of diagnosis of GS, ideally in the 
first 6 months of life
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should be shortened after the occurrence of the first BCC. 
In addition, recommendations for sun protection should be 
given in all patients.
Odontogenic keratocysts
Early diagnosis of these benign tumors is important to facili-
tate a conservative local treatment. Current recommenda-
tions, which combine yearly clinical examination to follow 
dental eruption beginning around age 2 and annual ortho-
panthogram using digital imaging starting at age 8, or sooner 
in cases of late dental eruption, have been limited to PTCH1 
PV carriers. To avoid irradiation linked to X-rays in these 
patients, the use of MRI would be preferred when as sensi-
tive as X-rays whenever possible.
Reducing imaging to once every 2 years when no cysts 
are observed and once every 3 years from age 30, may be 
suggested for long-term follow-up of these patients. As no 
jaw cysts have been described so far for SUFU-related GS, 
such screening is not necessary.
Medulloblastomas
The impact of early detection of medulloblastoma on the 
outcome of these tumors has not been demonstrated thus far. 
However, theoretically, early detection should allow diagno-
sis of small tumors before the occurrence of metastases and 
easier resection of these tumors. This theoretical advantage 
has to be balanced against the risk associated with seda-
tion required for good quality MRI in young children. The 
risk of medulloblastoma is clearly different according to the 
genetic background. In patients with PTCH1 PVs in whom 
the risk of medulloblastoma is probably under 2%, the need 
for screening for medulloblastoma is not obvious. However, 
parents must be informed of the oncological risks and these 
children should be followed clinically with neurological 
examinations and with a high index of suspicion during the 
first years of life, leading to prompt brain MRI, if symptoms 
or neurological signs appear.
In patients with germline SUFU PVs, in whom the risk 
of medulloblastoma is estimated to be around 8–9%, brain 
MRIs should be recommended during the first 5 years of 
life. Due to rapid progression of these tumors, brain MRI 
should be repeated every 3 to 4 months during the first 
3 years, since most tumors occur before age 3, and then 
every 6 months until age 5. Brain MRIs for tumor detection 
in healthy infant carriers are recommended without contrast 
agent, except for the first one which can be performed with 
a contrast agent. If a lesion is suspected, an additional MRI 
with contrast agent is necessary.
After treatment of medulloblastoma, follow-up should be 
prolonged and adapted to the risk of secondary tumors, such 
as meningioma, but also BCC and thyroid carcinomas if the 
patient has been treated with radiotherapy.
Meningiomas
The benefit and harms of screening for asymptomatic men-
ingioma is still a matter of debate especially since there 
are uncertainties about the most appropriate care for those 
tumors detected through systematic screening [40].
Due to the low incidence of meningioma in PTCH1 PV 
carriers, specific screening procedures for this tumor are 
not required. In SUFU PV carriers in whom the incidence 
is much higher, brain MRI every 3–5 years could be pro-
posed, beginning at age 30 years for patients with no pre-
vious medulloblastoma. For those previously treated with 
craniospinal irradiation, MRI of brain (+ / − spine) should 
be performed every 3–5 years starting after completion of 
medulloblastoma imaging follow-up.
Ovarian fibroma/ fibrothecomas
Although these tumors are benign, an early detection is 
important to facilitate conservative surgery which may be 
complicated due to the high incidence of bilateral and mul-
tifocal tumors. Patients and parents should be informed of 
the symptoms and especially of risk of torsion so that in case 
of abdominal pain, imaging evaluation can be performed 
urgently. For females with GS associated with a PTCH1 PV 
in whom the risk is probably around 5%, we recommend at 
least one pelvic ultrasound performed at the end of adoles-
cence (18y). In patients with a SUFU PV, a first pelvic ultra-
sound is recommended at 10 years of age and subsequent 
follow-up depends on the findings. Pelvic ultrasound every 
3 years is recommended if the first was normal. Monitoring 
should be more frequent in case of detection of a suspicious 
lesion. In patients in whom ovarian evaluation by ultrasound 
is not feasible, pelvic MRI should be discussed.
Cardiac tumors
A baseline cardiac ultrasound should be performed at the 
time of diagnosis of GS, ideally within the first 6 months 
of life.
Psychological and ethical issues
Like other predisposition syndromes, germline analysis 
for SUFU or PTCH1 PV raises psychological and ethical 
issues. Genetic counseling is proposed to families when 
phenotypic criteria are present, but it is important to keep 
in mind that genetic testing remains offered to families, 
who might be willing to know but others can also prefer 
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“not to know” which is a important right to defend. Find-
ing such information can be stressful for children and their 
parents, and psychological support has to be proposed. 
Families should also be offered time to think about genetic 
issues before launching genetic tests: indeed, finding a pre-
disposition syndrome involves lifelong monitoring, that 
may be difficult to live with. It also involves the possibility 
of genetic counseling for other family members, who may 
also be at risk, and communication about this risk can be 
difficult within some families. This is why genetic teams 
should include psychologists, who can help children and 
their parents faced with such tests to anticipate the conse-
quences. Compliance with the legal aspect of analyses is 
ensured by signing the consents to perform genetic analy-
ses. As far as possible, children, even young ones, should 
be involved in the process of their genetic research, with 
information and precautions appropriate to their age.
Conclusion
GS was described many years ago, but the identification 
of different underlying molecular genetic characteristics 
(PTCH1 or SUFU germline variants) has changed the way 
in which this predisposing syndrome is identified and has 
modified the phenotypic characteristics of the tumor risks 
historically described. There are still many uncertainties 
about the risk of tumors associated with GS. Given the 
rarity of this syndrome, the estimation of the risks is still 
not very precise and must be improved by studies on a 
larger number of patients with analysis taking into account 
ascertainment bias. Nevertheless, due to the risk of tumor, 
any patient with GS predisposition syndrome should ben-
efit from a specific genotype-based surveillance program 
as described in these recommendations. The evaluation 
of the feasibility and efficacy of these recommendations 
is necessary.
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